nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Antibacterial drug discovery—Then, now and the genomics future
|
Monaghan, Richard L. |
|
2006 |
71 |
7 |
p. 901-909 9 p. |
artikel |
2 |
Commensals upon us
|
Alekshun, M.N. |
|
2006 |
71 |
7 |
p. 893-900 8 p. |
artikel |
3 |
Crystallizing new approaches for antimicrobial drug discovery
|
Schmid, Molly B. |
|
2006 |
71 |
7 |
p. 1048-1056 9 p. |
artikel |
4 |
Dihydrofolate reductase inhibitors as antibacterial agents
|
Hawser, Stephen |
|
2006 |
71 |
7 |
p. 941-948 8 p. |
artikel |
5 |
Does the cell wall of bacteria remain a viable source of targets for novel antibiotics?
|
Silver, Lynn L. |
|
2006 |
71 |
7 |
p. 996-1005 10 p. |
artikel |
6 |
Editorial
|
Enna, S.J. |
|
2006 |
71 |
7 |
p. 891- 1 p. |
artikel |
7 |
Editorial Advisory Board
|
|
|
2006 |
71 |
7 |
p. iii- 1 p. |
artikel |
8 |
Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view
|
Lynch, A. Simon |
|
2006 |
71 |
7 |
p. 949-956 8 p. |
artikel |
9 |
Empirical antibacterial drug discovery—Foundation in natural products
|
Singh, Sheo B. |
|
2006 |
71 |
7 |
p. 1006-1015 10 p. |
artikel |
10 |
Glycopeptides: Update on an old successful antibiotic class
|
Pace, John L. |
|
2006 |
71 |
7 |
p. 968-980 13 p. |
artikel |
11 |
Natural products — The future scaffolds for novel antibiotics?
|
Butler, Mark S. |
|
2006 |
71 |
7 |
p. 919-929 11 p. |
artikel |
12 |
Practical applications and feasibility of efflux pump inhibitors in the clinic—A vision for applied use
|
Lomovskaya, Olga |
|
2006 |
71 |
7 |
p. 910-918 9 p. |
artikel |
13 |
Redefining penems
|
Dalhoff, Axel |
|
2006 |
71 |
7 |
p. 1085-1095 11 p. |
artikel |
14 |
Structure-based drug design meets the ribosome
|
Franceschi, François |
|
2006 |
71 |
7 |
p. 1016-1025 10 p. |
artikel |
15 |
Surveillance uncovers the smoking gun for resistance emergence
|
Verhoef, Jan |
|
2006 |
71 |
7 |
p. 1036-1041 6 p. |
artikel |
16 |
Targeting the forgotten transglycosylases
|
Halliday, Judy |
|
2006 |
71 |
7 |
p. 957-967 11 p. |
artikel |
17 |
The evolution of peptide deformylase as a target: Contribution of biochemistry, genetics and genomics
|
Yuan, Zhengyu |
|
2006 |
71 |
7 |
p. 1042-1047 6 p. |
artikel |
18 |
The forgotten Gram-negative bacilli: What genetic determinants are telling us about the spread of antibiotic resistance
|
Gootz, Thomas D. |
|
2006 |
71 |
7 |
p. 1073-1084 12 p. |
artikel |
19 |
The historical delivery of antibiotics from microbial natural products—Can history repeat?
|
Peláez, Fernando |
|
2006 |
71 |
7 |
p. 981-990 10 p. |
artikel |
20 |
The role of pharmacodynamic research in the assessment and development of new antibacterial drugs
|
Lister, Philip D. |
|
2006 |
71 |
7 |
p. 1057-1065 9 p. |
artikel |
21 |
Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations
|
Buynak, John D. |
|
2006 |
71 |
7 |
p. 930-940 11 p. |
artikel |
22 |
Unmet medical needs in antibacterial therapy
|
Rice, Louis B. |
|
2006 |
71 |
7 |
p. 991-995 5 p. |
artikel |
23 |
Use of constraint-based modeling for the prediction and validation of antimicrobial targets
|
Trawick, John D. |
|
2006 |
71 |
7 |
p. 1026-1035 10 p. |
artikel |
24 |
Use of genomics to select antibacterial targets
|
Pucci, Michael J. |
|
2006 |
71 |
7 |
p. 1066-1072 7 p. |
artikel |
25 |
When will the genomics investment pay off for antibacterial discovery?
|
Mills, Scott D. |
|
2006 |
71 |
7 |
p. 1096-1102 7 p. |
artikel |